19:19:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-06-18 Bokslutskommuniké 2024
2024-03-13 Kvartalsrapport 2024-Q3
2023-12-12 Kvartalsrapport 2024-Q2
2023-10-18 Ordinarie utdelning SDOS 0.00 SEK
2023-10-17 Årsstämma 2024
2023-09-13 Kvartalsrapport 2024-Q1
2023-06-15 Bokslutskommuniké 2023
2023-03-08 Kvartalsrapport 2023-Q3
2022-12-07 Kvartalsrapport 2023-Q2
2022-10-18 Ordinarie utdelning SDOS 0.00 SEK
2022-10-17 Årsstämma 2023
2022-09-13 Kvartalsrapport 2023-Q1
2022-06-28 Bokslutskommuniké 2022
2022-03-11 Kvartalsrapport 2022-Q3
2021-12-14 Kvartalsrapport 2022-Q2
2021-10-21 Ordinarie utdelning SDOS 0.00 SEK
2021-10-20 Årsstämma 2022
2021-09-23 Kvartalsrapport 2022-Q1
2021-06-29 Bokslutskommuniké 2021
2021-03-10 Kvartalsrapport 2021-Q3
2020-12-16 Kvartalsrapport 2021-Q2
2020-10-07 Ordinarie utdelning SDOS 0.00 SEK
2020-10-06 Årsstämma 2021
2020-09-25 Kvartalsrapport 2021-Q1
2020-06-26 Bokslutskommuniké 2020
2020-03-10 Kvartalsrapport 2020-Q3
2019-12-18 Kvartalsrapport 2020-Q2
2019-10-09 Ordinarie utdelning SDOS 0.00 SEK
2019-10-08 Årsstämma 2020
2019-09-12 Kvartalsrapport 2020-Q1
2019-06-28 Bokslutskommuniké 2019
2018-12-14 Kvartalsrapport 2019-Q2
2018-10-03 Ordinarie utdelning SDOS 0.00 SEK
2018-10-02 Årsstämma 2019
2018-06-28 Bokslutskommuniké 2018
2018-03-22 Kvartalsrapport 2018-Q3
2017-12-15 Kvartalsrapport 2018-Q2
2017-10-03 Ordinarie utdelning SDOS 0.00 SEK
2017-10-02 Årsstämma 2018
2017-09-29 Kvartalsrapport 2018-Q1
2017-06-28 Bokslutskommuniké 2017
2017-03-22 Kvartalsrapport 2017-Q3
2016-12-15 Kvartalsrapport 2017-Q2
2016-09-21 Ordinarie utdelning SDOS 0.00 SEK
2016-09-20 Kvartalsrapport 2017-Q1
2016-09-20 Årsstämma 2017
2016-06-30 Bokslutskommuniké 2016
2016-03-15 Kvartalsrapport 2016-Q3
2015-12-11 Kvartalsrapport 2016-Q2
2015-09-24 Ordinarie utdelning SDOS 0.00 SEK
2015-09-23 Årsstämma 2016
2015-09-23 Kvartalsrapport 2016-Q1
2015-06-23 Bokslutskommuniké 2015
2015-03-26 Kvartalsrapport 2015-Q3
2014-12-19 Kvartalsrapport 2015-Q2
2014-10-14 Årsstämma 2015
2014-09-24 Ordinarie utdelning SDOS 0.00 SEK
2014-09-23 Kvartalsrapport 2015-Q1
2014-06-13 Bokslutskommuniké 2014

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Scandidos är verksamt inom medicinteknik. Bolaget erbjuder produkter och system för kvalitetssäkring av avancerad strålterapi mot cancer. Systemen analyserar stråldosen inför och under pågående strålbehandling. Bolaget grundades under 2002 och den första produkten lanserades 2006. Sedan starten har Scandidos levererat produkter till strålterapikliniker på global nivå. Huvudkontoret ligger i Uppsala.
2021-07-06 07:00:00
The Pôle d’Imagerie et de Cancérologie du Pont Saint Vaast, with its four sophisticated radiotherapy clinics, has selected ScandiDos’ motion management QA solution to verify treatments delivered by the advanced Synchrony® feature for the Radixact® System.

The Pôle d’Imagerie et de Cancérologie du Pont Saint Vaast, a private hospital group located in the North of France, has four radiotherapy clinics with treatment machines from Accuray, Elekta and Varian. The latest addition to their treatment machines is a Radixact® system with Synchrony® from Accuray, a state-of-the-art tumor target tracking system for adaptive radiotherapy treatments.

ScandiDos has been selected to supply the Pôle d’Imagerie et de Cancérologie du Pont Saint Vaast with pre-treatment quality assurance systems for their new Radixact® system as well as for their Elekta and Varian machines at the group´s different radiotherapy clinics.

“When implementing the Accuray Radixact® with Synchrony®, it became obvious to us to invest in the Delta4 HexaMotion. This solution was the best choice in order to control treatments of moving targets with excellent precision. In partnership with ScandiDos, we will act as a reference center for the Delta4 HexaMotion.

We have been performing IMRT / VMAT treatments since 2011 as well as stereotaxy treatments on various machines. The advantage of the Delta4 is that it is a detector that is compatible with all these equipment. Its 3D representation of the measured dose is a real advantage.

We find in Scandidos products what could characterize the Nordic spirit: simple and effective!”, said Esther Bouche, Physics Team Manager – Medical Physicist.

Personalized treatments require accurate and efficient QA of moving targets

The importance of tailoring patient treatments to the specific needs of each patient has resulted in the Pôle d’Imagerie et de Cancérologie du Pont Saint Vaast investing in different brands of treatment machines, with the latest addition being the Accuray Radixact® with the Synchrony® motion synchronization technology. Clinics in possession of advanced tumor tracking machines require an equally sophisticated QA system that can recreate tumor movements to ensure the best possible treatment outcome. ScandiDos, a world leader in QA and dosimetry, is the preferred partner for these clinics.

Simulates patient breathing and tumor movements

ScandiDos QA solutions ensure that the tumor tracking function of the treatment machine works. Delta4 HexaMotion is a motion platform that recreates the movement of the tumor in six dimensions, whereas the Delta4 Phantom+ measures the 4D dose distribution and shows exactly where the dose is delivered. The new Independent Motion Platform option for the Delta4 HexaMotion is developed in close collaboration with Accuray, and its purpose is to mimic the breathing of the patient independently of the motion of the tumor. Thus, providing medical physicists with a realistic pre-treatment verification of the delivered treatment for machines such as Accuray Radixact® with Synchrony®.

“We at ScandiDos are very impressed with the extraordinary cancer care being delivered at Pôle d’Imagerie et de Cancérologie du Pont Saint Vaast and are proud to be supporting them with tools to secure the highest level of quality in their radiotherapy treatments. The solutions we have developed specifically for QA of moving targets with our Delta4 Phantom+ coupled with HexaMotion have been very well received by the market and we look forward to cooperate with Pôle d’Imagerie et de Cancérologie du Pont Saint Vaast to continue to develop our solutions.“ said Gustaf Piehl, President & CEO of ScandiDos.